November 10, 2009 – Covidien said yesterday it will voluntarily contraindicate the use of its Optimark gadoversetamide injection, a gadolinium-based contrast agent (GBCA), in magnetic resonance imaging (MRI) procedures involving patients with severe renal impairment.
